Table 4.
Historical incidence of AZA‐induced leukopenia, compared with incidence among prospective genetic screening study participants
| Variants | Year | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total | 2018–2021 | ||
| Retrospective cohort | Prospective cohort | ||||||||
| (Historical incidence, %) | (Actual incidence, %) | ||||||||
| (95% CI) | (95% CI) | ||||||||
| AZA‐related leukopenia | |||||||||
| ≥Grade 4 | 4.4% | 4.3% | 2.6% | 5.0% | 5.7% | 4.6% | 4.4% (3.7–5.7) | 0% (0–0.5) | 5.1 ×10 −14 a |
| ≥ Grade 3 | 5.0% | 6.6% | 3.0% | 5.0% | 5.9% | 6.0% | 5.2% (4.4–6.0) | 0.3% (0–0.6) | 1.7 × 10 −13 a |
| ≥ Grade 2 | 5.7% | 8.8% | 6.3% | 8.4% | 7.8% | 10.5% | 7.6% (6.7–8.6) | 0.4% (0–0.8) | 9.3 × 10 −20 a |
Bold values represent the significant P values for comprasion.
≥ Grade 2 leukopenia indicates WBC ≤ 3,000 cells/μL after AZA intake.
≥ Grade 3 leukopenia indicates WBC ≤ 2,000 cells/μL after AZA intake.
≥ Grade 4 leukopenia indicates WBC ≤ 1,000 cells/μL after AZA intake.
AZA, azathioprine; CI, confidence interval; WBC, white blood cell.
a
P values were calculated by comparing the historical incidence and actual incidence among study participants.